Thus, operating profit recorded since the beginning of the year dropped 63%, standing at 1,178 million euros, with inflows (total value) reaching 22,204 million euros, a 32% decrease compared to 2020.The company notes that excluding the vaccine against covid-19, profits have increased 21% since the beginning of the year, corresponding to 20,265 million euros.
The company notes that it has grown in relation to cancer drugs and has established capabilities in rare disease treatments through the acquisition of pharmaceutical company Alexion.
Medicines to treat rare diseases have made progress thanks to innovation and medical needs, according to the same note from AstraZeneca.
The company’s Chairman of the Board, Pascal Soriot, said that “scientific leadership” has helped growth as the acquisition of Alexion allows the drugmaker to achieve “transformative therapies” aimed at patients around the world.
The company’s debt increased by 10,980 million euros in the first nine months of 2021 to 21,564 million euros, due to the acquisition of Alexion.
Source: Jornal de Negócios by www.jornaldenegocios.pt.
*The article has been translated based on the content of Jornal de Negócios by www.jornaldenegocios.pt. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!